Citations

Clear

6273 citation(s) found for "To, Andrew".

Development of a Uniform Apheresis Case Report Form for Standardized Collection of Apheresis Data
Johnson, Andrew D., Szczepiorkowski, Zbigniew M. , Karam, Oliver , Nellis, Marianne E. , Schwartz, Joseph, Wu, Yanyun , Armendariz, Tomas , Burgstaler, Edwin A. , Collins, Laura , Geile, Kira, Pavenski, Katerina , Sanchez, Amber P. , Witt, Volker, Muthusamy, Amutha, Ramesh, Vidhyalakshmi , Thao, Mai See , Chlebeck, Therese M., Zantek, Nicole D. , Karam, Oliver , Armendariz, Tomas , Burgstaler, Edwin, Zantek, Nicole D , Balogun, Rasheed A. , Schneiderman, Jennifer , Winters, Jeffrey L. , Pavenski, Katerina , Pederson, Thomas

Mayo Clinic

Journal of Clinical Apheresis | October 18, 2024 | Volume: 39 | Issue: 5 | Pages: No page available

10.1002/jca.22146 | PMID 39420527 Get It

ABSTRACTApheresis is performed worldwide for an increasing number of indications. The development of common data elements (CDE) for apheresis related areas may facilitate conduct of new research, enhance quality initiatives including benchmarking, and improve patient care. This report describes the systematic development of the Uniform Apheresis Case Report Form (UACRF) as part of the Apheresis in the United States (ApheresUS) program. A consensus panel of 17 diverse experts in apheresis, related specialties, and electronic case report form (eCRF), and database development was assembled. The panel met via online conferencing from November 17, 2020 to December 1, 2021. A draft document was posted online for public comment from October 11, 2021 to November 10, 2021. Feedback was collected using an online survey tool. The consensus panel revised the UACRF. This version was converted to an eCRF with additional changes made to improve usability in this format. The final version of the UACRF was created on August 24, 2023. The UACRF contains 16 modules: procedure and subject eligibility, patient demographics, general procedure information, laboratory parameters, vascular access, common procedure elements, eight procedure specific modules (mononuclear cell collection and seven therapeutic modalities), outcomes, and site information. A total of 137 data elements were created, including 57 with one or more subelements. The UACRF is the first systematic attempt to develop CDE for therapeutic apheresis and white blood cell collections. Further validation of the UACRF is necessary to confirm the tool's ability to collect the relevant data elements and determine the usability of the form.
EUS–guided therapies for primary and secondary prophylaxis in gastric varices—An updated systematic review and meta-analysis
Nguyen, Andrew K. L., Deliwala, Smit , Ramai, Daryl , Kassab, Lena L., Muthusamy, Arunkumar, Kamal, Faisal, Adler, Douglas G., Chandan, Saurabh , Nguyen, Andrew Khoi, Mohan, Babu P. , Facciorusso, Antonio , Bilal, Mohammad , Samanta, Jayanta

Mayo Clinic

Endoscopic Ultrasound | October 17, 2024 | Volume: 12 | Issue: 4 | Pages: 351-361

10.1097/eus.0000000000000017 | PMID 37795350 Get It

Abstract Background and Objectives Gastric varices (GVs) are associated with a higher risk of uncontrolled bleeding and death when compared with esophageal varices. While endoscopic glue injection therapy has been traditionally used for secondary prophylaxis in GV, data regarding primary prophylaxis continue to emerge. Recently, EUS–guided therapies have been used in GV bleeding. Methods We conducted a comprehensive search of several major databases from inception to June 2022. Our primary goals were to estimate the pooled rates of treatment efficacy, GV obliteration, GV recurrence, and rebleeding with EUS-guided therapy in primary and secondary prophylaxis. Overall adverse events and technical failures were assessed. Random-effects model was used for our meta-analysis, and heterogeneity was assessed using the I 2 % statistics. Results Eighteen studies with 604 patients were included. In primary prophylaxis, pooled rate of GV obliteration was 90.2% (confidence interval [CI], 81.1–95.2; I 2 = 0). With combination EUS–glue and coil therapy, the rate was 95.4% (CI, 86.7%–98.5%; I 2 = 0). Pooled rate of posttherapy GV bleeding was 4.9% (CI, 1.8%–12.4%; I 2 = 0). In secondary prophylaxis, pooled rate of treatment efficacy was 91.9% (CI, 86.8%–95.2%; I 2 = 12). With EUS-glue, EUS-coil, and combination EUS–glue and coil, the rates were 94.3% (CI, 88.9%–97.1%; I 2 = 0), 95.5% (CI, 80.3%–99.1%; I 2 = 0), and 88.7% (CI, 76%–95.1%; I 2 = 14), respectively. Pooled rate of GV obliteration was 83.6% (CI, 71.5%–91.2%; I 2 = 74). With EUS-glue, EUS-coil, and combination EUS–glue and coil, the rates were 84.6% (CI, 75.9%–90.6%; I 2 = 31), 92.3% (CI, 81.1%–97.1%; I 2 = 0), and 84.5% (CI, 50.8%–96.7%; I 2 = 75), respectively. Pooled rates of GV rebleeding and recurrence were 18.1% (CI, 13.1%–24.3%; I 2 = 16) and 20.6% (CI, 9.3%–39.5%; I 2 = 66), respectively. Conclusion Our analysis shows that EUS-guided therapy for GVs is technically feasible and clinically successful in both primary and secondary prophylaxis of GV.
Carfilzomib Prescribing Patterns and Outcomes for Relapsed or Refractory Multiple Myeloma: A Real-World Analysis
Dong, Sharlene , Banerjee, Rahul , Khan, Adeel , Wang, Xiaoliang , Afghahi, Anosheh , Afrough, Aimaz , Janakiram, Murali , Cowan, Andrew J. , Banerjee, Rahul , Wang, Xiaoliang , Janakiram, Murali , Wang, Mengru , Wang, Bo , Sperling, Adam S. , Anderson, Larry D. , Rajkumar, S. Vincent , Kaur, Gurbakhash

Mayo Clinic

No container title available | October 17, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4839164/v1 Get It

Abstract Despite the widespread use of carfilzomib (K) in relapsed/refractory multiple myeloma (RRMM), there is no consensus on optimal K dose in milligrams per square meter (mg/m2) or dosing schedule. We assessed three modern K prescribing patterns in RRMM using a large United States electronic health record-derived database. Our final cohort (n = 486) included 136 patients (28.0%) who received K 56 mg/m2 once weekly (K56-1x), 86 (17.7%) who received 56 mg/m2 twice weekly (K56-2x), and 264 (54.3%) who received 70 mg/m2 once weekly (K70-1x). Between 2016 and 2023, once-weekly dosing became more common: K70-1x proportions changed from 21.1% in 2016 to 50.6% in 2023, K56-1x from 15.8% to 37.0%, and K56-2x from 63.2% to 12.3%. Median real-world progression-free survival was 13.0 months [95% confidence interval (CI) 11.2-20.7] for K56-1x, 13.2 months (95% CI 9.0-28.1 months) for K56-2x, and 10.9 months (95% CI 9.9-15.3 months) for K70-1x; these differences were not statistically significant (log-rank p = 0.46). The prevalence of heart failure was comparable (<5% in all cohorts). In summary, our findings do not support improved outcomes with twice-weekly carfilzomib in RRMM. K56-1x may provide the best balance of efficacy, safety, and avoidance of time toxicity from frequent infusions.
Feasibility of thin-slice, low noise images created using multi-kernel synthesis to replace multiple image series in head CT
Diehn, Felix E. , Nagelschneider, Alex A. , Passe, Theodore J. , Nelson, Brandon , Cardona, Daniel Gomez , Huber, Nathan R. , Missert, Andrew D, Yu, Lifeng , Johnson, Matthew P. , Holmes, David R. , Lee, Yong S. , Thorne, Jamison E. , Diehn, Felix E , DeLone, David R. , Nelson, Brandon J, Gomez Cardona, Daniel G , Thorne, Jamison E , Fletcher, Joel G , Inoue, Akitoshi , Missert, Andrew D, Yu, Lifeng , McCollough, Cynthia H. , Fletcher, Joel G.

Mayo Clinic

Acta Radiologica | October 17, 2024 | Volume: 65 | Issue: 11 | Pages: 1411-1421

10.1177/02841851241280365 | PMID 39415759 Get It

Background SynthesiZed Improved Resolution and Concurrent nOise reductioN (ZIRCON) is a multi-kernel synthesis method that creates a single series of thin-slice computed tomography (CT) images displaying low noise and high spatial resolution, increasing reader efficiency and minimizing partial volume averaging. Purpose To compare the diagnostic performance of a single set of ZIRCON images to two routine clinical image series using conventional CT head and bone reconstruction kernels for diagnosing intracranial findings and fractures in patients with trauma or suspected acute neurologic deficit. Material and Methods In total, 50 patients underwent clinically indicated head CT in the ER (15 normal, 35 abnormal cases). A non-reader neuroradiologist established the reference standard. Three neuroradiologists reviewed two routine clinical series (head and bone kernels) and a single ZIRCON series, detecting intracranial findings or fractures and rating confidence (0–100). Sensitivity, specificity, and jackknife free-response receiver operating characteristic (JAFROC) figure of merit (FOM) were compared (limit of non-inferiority: −0.10). Results ZIRCON and conventional images demonstrated comparable performance for fractures (sensitivity: 51.5% vs. 54.5%; specificity: 40.2% vs. 34.2%) and intracranial findings (sensitivity: 88.2% vs. 91.4%; specificity: 77.2% vs. 73.7%).The estimated difference of JAFROC FOM demonstrated ZIRCON non-inferiority for acute pathologies overall (0.003 [95% CI=−0.051–0.057]) and fractures (0.048 [95% CI=−0.050–0.145]) but not for intracranial findings alone (−0.024 [95% CI=−0.100–0.052]). Conclusion Thin-slice, low noise, and high spatial resolution images can be created to display intracranial findings and fractures replacing multiple images series in head CT with similar performance. Future studies in more patients and further algorithmic development are warranted.
Stenosis of the glomerulotubular neck in progressive chronic kidney disease
Đenić, Aleksandar , Aperna, Fnu, Sharma, Vidit , Denic, Aleksandar , Cohen, Eric P. , Mullan, Aidan F. , Barisoni, Laura , Gibson, Ian W. , Rule, Andrew D.

Mayo Clinic

Nephrology Dialysis Transplantation | October 17, 2024 | Volume: 40 | Issue: 5 | Pages: 917-928

10.1093/ndt/gfae234 | PMID 39415419 Get It

ABSTRACT Background Morphology and morphometric evaluation of lesions beyond conventional parameters can inform the pathophysiology of chronic kidney disease (CKD). We sought to determine whether the occurrence of glomerulotubular neck stenoses associates with progressive CKD. Methods We evaluated the normal parenchyma from radical nephrectomies removed for tumor between 2000 and 2021 and analyzed cortex for stenoses of the glomerulotubular neck. Stenosis of the glomerulotubular neck is defined a focal narrowing for which the draining tubule has a greater diameter than at the neck. Progressive CKD was defined as dialysis, kidney transplantation, sustained estimated glomerular filtration rate (eGFR) &lt;10 mL/min/1.73 m2 or sustained 40% decline from the post-nephrectomy eGFR. Each case of progressive CKD was age- and sex-matched to two controls without progressive CKD. Logistic regression models assessed the risk of progressive CKD with stenotic necks adjusting for other histological features, kidney function and CKD risk factors. Results There were 65 cases with a mean of 255 glomeruli and 130 controls with a mean of 329 glomeruli. Among both cases and controls, 5% of glomeruli showed visible glomerulotubular necks. The proportion of necks that were stenotic was higher in cases than controls (35% vs 11%, P &lt; .0001). Stenotic necks associated with progressive CKD independent of other histologic and clinical characteristics. Conclusion Glomerulotubular neck stenosis is associated with development of progressive CKD.
The Brief Case: Human leptospirosis acquired in Minnesota and diagnosed using 16S ribosomal RNA gene PCR/next-generation sequencing of blood
Kim, Myeongji , Enzler, Mark J., Pritt, Bobbi S. , Kumlien, Aaron C., Theel, Elitza S. , Norgan, Andrew P. , Paisie, Taylor K. , Patel, Robin , Patel, Robin , Pritt, Bobbi S , Norgan, Andrew P , Wolf, Matthew J.

Mayo Clinic

Journal of Clinical Microbiology | October 16, 2024 | Volume: 62 | Issue: 10 | Pages: No page available

10.1128/jcm.00572-24 Get It

Gábor Transform-Based Antibody Quantitation in Serum: An Interlaboratory Liquid Chromatography/High-Resolution Mass Spectrometry Investigation
Meldrum, Kayd L., Swansiger, Andrew K. , Koscho, Jacob, Miller, Lily, Sausen, John , Maus, Anthony , Ladwig, Paula M. , Prell, James S. , Maus, Anthony D , Willrich, Maria A V, Prell, James S , Miller, Lily, Willrich, Maria Alice V.

Mayo Clinic

Analytical Chemistry | October 16, 2024 | Volume: 96 | Issue: 43 | Pages: 17413-17422

10.1021/acs.analchem.4c04470 | PMID 39412157 Get It

NCCN Guidelines® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024
Cohen, Joshua G. , Miller, David S. , Robertson, Sharon E. , Hendrickson, Andrea Wahner, Gray, Heidi J. , Hakam, Ardeshir, Jain, Angela, Konecny, Gottfried E. , Moroney, John W. , Ratner, Elena , Schorge, John O., Werner, Theresa L. , Chen, Lee-may, DeRosa, Marie, Eisenhauer, Eric , Leiserowitz, Gary S. , Litkouhi, Babak , McHale, Michael , Percac‐Lima, Sanja , Rodabaugh, Kerry J. , Vargas, Roberto , Jones, Frankie, Kovách, E, Hang, Lisa E., Ramakrishnan, Swathi , Armstrong, Deborah K. , Miller, David S , Liu, Joyce F. , Berchuck, Andrew , Backes, Floor , Grisham, Rachel Nicole , Leath, Charles A , Martin, Lainie P. , Matei, Daniela , Barroilhet, Lisa , Uppal, Shitanshu , Gershenson, David M. , Thaker, Premal H. , Zsíros, Emese , Behbakht, Kian , Kovach, Emily, Alvarez, Ronald D.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | October 16, 2024 | Volume: 22 | Issue: 8 | Pages: 512-519

10.6004/jnccn.2024.0052 | PMID 39413835 Get It

The NCCN Guidelines for Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer provide multidisciplinary diagnostic workup, staging, and treatment recommendations for this disease. These NCCN Guidelines Insights detail how the evolution of the use of PARP inhibitors as maintenance and single-agent regimens for the treatment of ovarian cancer informed panel recommendations in the guidelines.
Dried blood spot improves global access to aquaporin‐4‐IgG testing for neuromyelitis optica
Vorasoot, Nisa , Abdulrahman, Yahya, Mateen, Farrah J. , Fryer, James P., Redenbaugh, Vyanka , Sagen, Jessica, Jenkins, Sarah M. , Gorsh, Amy P., Chen, John J. , Ζεκερίδου, Αναστασία , Mills, John R. , Pittock, Sean J. , Pittock, S J , Abdulrahman, Yahya J, Mateen, Farrah , Sagen, Jessica A., Zekeridou, Anastasia , McKeon, Andrew , Flanagan, E P , Chen, John J , Vorasoot, Nisa , Musubire, Abdu Kisekka , McKeon, Andrew , Flanagan, Eoin P.

Mayo Clinic

Annals of Clinical and Translational Neurology | October 15, 2024 | Volume: 11 | Issue: 11 | Pages: 2855-2865

10.1002/acn3.52178 | PMID 39406378 Get It

AbstractObjectiveThis study aimed to evaluate the diagnostic accuracy of dried blood spot (DBS) compared with conventional serum Aquaporin‐4‐IgG (AQP4‐IgG) testing.MethodsProspective multicenter diagnostic study was conducted between April 2018 and October 2023 across medical centers in the United States, Uganda, and the Republic of Guinea. Neuromyelitis optica spectrum disorder (NMOSD) patients and controls collected blood on filter paper cards along with concurrent serum samples. These samples underwent analysis using flow cytometric live‐cell‐based assays (CBA) and enzyme‐linked immunosorbent assay (ELISA) to determine AQP4 serostatus. The accuracy of AQP4‐IgG detection between DBS and serum (gold standard) was compared.ResultsAmong 150 participants (47 cases, 103 controls), there was a strong correlation between DBS and serum samples (Spearman's correlation coefficient of 0.82). The AUC was 0.97 (95% CI: 0.92–0.99). AQP4‐IgG detection through DBS showed 87.0% sensitivity (95% CI: 0.74–0.95) and 100% specificity (95% CI: 0.96–1.00) using CBA, and 65.2% sensitivity (95% CI: 0.43–0.84) and 95.2% specificity (95% CI: 0.76–0.99) using ELISA. Serum ELISA demonstrated 69.6% sensitivity (95% CI: 0.47–0.87) and 98.4% specificity (95% CI: 0.91–0.99). The stability of DBS in detecting AQP4‐IgG persisted over 24 months for most cases.InterpretationThe DBS represents a viable alternative for detecting AQP4‐IgG in resource‐limited settings to diagnose NMOSD, offering high sensitivity and specificity comparable to serum testing. Moreover, DBS has low shipping costs, is easy to administer, and is suitable for point‐of‐care testing.